N/A N=9 Long QT Syndrome and Sleep Apnea
Long QT Syndrome · Sleep Apnea
Primary: QT Interval (Corrected) Baseline Visit — 453.4 square root of seconds — p=0.73
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1 Diltiazem in Jervell and Lange-Nielsen Syndrome
Jervell and Lange Nielsen Syndrome
Primary: QT Interval — 623 ms
Phase 1 N=13 Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome
LQT2 Syndrome
Primary: Change From Baseline in Standard 12-Lead Electrocardiogram (ECG) Daytime QT Interval Corrected For Heart Rate Using The Fridericia Formula (QTcF) (AUC0-8)/8 at Day 3…
N/A N=35 Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
Long QT Syndrome · Cardiac Repolarization
Primary: QTc Response to Exercise on Versus Off Beta-blocker. — 320; 317; 317; 315 ms
Phase 2 N=25 Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
Long QT Syndrome
Primary: Change in QTc Duration at 2 Months — 503; 497 miliseconds — p=0.7958
N/A N=22 QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)
Atrial Arrhythmia · QT Interval, Variation in · Arrhythmias, Cardiac
Primary: QT Intervals During Antiarrhythmic Loading Hospitalization — 21.8 milliseconds
Phase 4 N=14 Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
Long QT Syndrome
Primary: Baseline (Pre-ibutilide) Individualized Rate-corrected QT Interval (QTF) — 393; 399; 399 ms — p=0.09
Phase 2 N=19 Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening
Prolonged QT Interval in EKG and Sudden Death
Primary: Baseline (Pre-Ibutilide) QTcI Intervals — 412; 419 ms — p=0.04
Phase 1 N=22 Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or…
Phase 1 N=22 Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
Drug-induced Surface ECG Changes
Primary: Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc — 6.5; 2.3; 32.1; 5.1 ms — p=<0.05
Phase 4 N=27 Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
Long QT Syndrome · Abnormalities, Drug-Induced
Primary: Baseline (Pre-ibutilide) QT-F Intervals — 417; 421; 413; 414 ms — p=0.07
Phase 1 N=48 Staccato Prochlorperazine Thorough QT/QTc
Cardiotoxicity
Primary: Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.493; 5.229 milliseconds
Phase 1 N=60 CiPA Phase 1 ECG Biomarker Validation Study
Drug-induced QT Prolongation · Pharmacokinetics · Pharmacodynamics
Primary: Change From Baseline J-Tpeakc With "Balanced Ion Channel" Drugs (Ranolazine, Verapamil, Lopinavir / Ritonavir) — -8.3; -7.8; -11.5; -10.9 ms
Phase 1 N=36 A TQT Study of Effect of M2951 on Cardiac Repolarization
Healthy
Primary: Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib — -1.62; -2.28 milliseconds
Phase 1 N=48 Staccato Loxapine Thorough QT/QTc Study
Thorough QT/QTc Study
Primary: Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.418 mseconds
Phase 1 N=47 This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)
Healthy
Primary: Change From Baseline in QTcF at That Timepoint Between 20 Minutes to 24 Hours After Drug Administration Where the Difference of Means in QTcF Changes From Baseline…
Phase 1 N=26 QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Primary: Mean Time-matched, Baseline Corrected QTcF at Any Time Point Postdosing. — 2; 11 msec
Phase 2 N=51 Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Metastatic Breast Cancer
Primary: Change From Baseline in Mean Duration of the QTc Interval — 1.2; -1.0; -4.0; -0.1 milliseconds
Phase 1 N=32 Food and Insulin Effect on QT/QTC Interval of ECG
Effects of Different Meals on the QT/QTc Interval · Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use · C-Peptide Effects on the QT/QTc Interval
Primary: The Effect of Food (Fasted and Fed State) on the Degree of QT Prolongation Caused by Moxifloxacin — 14.4; 11.6 ms — p=0.05
Phase 4 N=50 Safety of Argatroban Infusion in Conduction Disturbances
Stable Coronary Artery Disease (CAD) · Unstable Angina (Troponin Negative)
Primary: Mean Difference in QTc Interval Between ECG-2 and ECG-1 (ITT Population) — 0.94 milliseconds
Phase 1 N=60 CP-690,550 Thorough QTc Study
Healthy
Primary: Mean Time-Matched Difference in QTcF Intervals Between CP-690,550 Compared to Placebo at 0.25 Hour Post-Dose — 416.48; 417.77 milliseconds (msec)
Phase 1 N=48 Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)
Anesthesia; Adverse Effect · Cardiac Arrhythmia
Primary: Change-from-baseline in QTc Interval — 2.1; 5.1; -0.1; 4.1 ms — p=<0.05
Phase 1 N=70 Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
QT Intervals Changes · QTc Intervals Changes
Primary: Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Omecamtiv Mecarbil Dosing in Part B — -2.6…
Phase 1 N=40 Thorough QT Study of Intravenous Amisulpride
Healthy
Primary: Maximal Mean ΔΔQTcF — 5.0; 23.4; 0.8; 12.3 milliseconds
Phase 1 N=83 Guanfacine Immediate-release Electrocardiogram Results (QTc) Study
Healthy Volunteers
Primary: Change From Baseline in Electrocardiogram Results (QTcNi) at Time of Maximum Plasma Concentration (Tmax) on Day 1 — -3.37; 12.96; -0.94; -0.91 msec
Phase 1 N=9 A Study To Assess The Effect Of Linezolid On QTc Interval
Bacterial Infections
Primary: Cohort 1: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 1; 3; 2; 0 participants
Phase 1 N=112 A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects
Autoimmune Diseases
Primary: Change-from-baseline QT Interval Corrected for Heart Rate Using Fridericia's Method (QTcF) — 1.5; 0.9 msec
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
Phase 1 N=44 A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects
Healthy
Primary: Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 0.5 Hour Post-Dose — 404.09; 408.92…
Phase 4 N=50 Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
Prolonged QTc Interval
Primary: Maximum Difference in Change From Baseline in ddQTcF Following a Single Dose of 33 mg/kg Deferiprone — 1.4; -1.6 milliseconds